MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Kodu・Aktsiate loetelu・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Avatud

4.77

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.71

Max

4.77

Põhinäitajad
By Trading Economics
Sissetulek	-10M -7.7M
Müük	-10M 529K
Kasumimarginaal	-1,463.516
Töötajad	44
EBITDA	-10M -7.7M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. märts 2026

Turustatistika
By TradingEconomics
Turukapital	28M 908M
Eelmine avamishind	4.77
Eelmine sulgemishind	4.77

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

3.255 / 3.365 Toetus ja vastupanu

Arbutus Biopharma Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. jaan 2026, 22:45 UTC

Suurimad hinnamuutused turgudel

GH Research Shares Up, Plans to Provide Update on New Drug Application

4. jaan 2026, 23:50 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Geopolitical Risks After Maduro's Ouster -- Market Talk

4. jaan 2026, 23:50 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Decline After Removal of Venezuela's Maduro -- Market Talk

4. jaan 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

4. jaan 2026, 23:40 UTC

Market Talk

Uudisväärsed sündmused

Markets Mostly Calm as Venezuelan Raid Weighed -- Market Talk

4. jaan 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Declines on Oversupply Worries After Maduro's Ouster -- Market Talk

4. jaan 2026, 23:19 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

4. jaan 2026, 23:19 UTC

Market Talk

Uudisväärsed sündmused

ONGC Could Receive $500M in Unpaid Dividends From U.S. Takeover of Venezuelan Oil -- Market Talk

4. jaan 2026, 23:17 UTC

Uudisväärsed sündmused

Spot Gold Rises 0.8% to $4,365.24/oz

4. jaan 2026, 23:16 UTC

Uudisväärsed sündmused

Spot Gold Rises After U.S.' Removal of Venezuela's Maduro

4. jaan 2026, 23:14 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Fall 0.6%; Front-Month Brent Crude Oil Futures Drop 0.5%

4. jaan 2026, 23:13 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Fall After Ouster of Venezuela's Maduro

4. jaan 2026, 23:12 UTC

Market Talk

Uudisväärsed sündmused

Reliance Industries' Could Benefit from U.S. Takeover of Venezuelan Oil -- Market Talk

4. jaan 2026, 22:37 UTC

Market Talk

Uudisväärsed sündmused

Gold Can Gain From Flight to Quality, Central Bank Demand After Maduro Ouster -- Market Talk

4. jaan 2026, 21:00 UTC

Tulu

An On-Time Jobs Report. Plus, Albertsons, Constellation, Jefferies, and More Stocks to Watch this Week. -- Barrons.com

4. jaan 2026, 20:49 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

4. jaan 2026, 20:49 UTC

Market Talk

Uudisväärsed sündmused

Jitters About Potential for U.S. Actions Elsewhere Could Grow -- Market Talk

3. jaan 2026, 18:59 UTC

Uudisväärsed sündmused

Update: Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3. jaan 2026, 17:42 UTC

Uudisväärsed sündmused

The Oil Sector's Biggest Winners and Losers From Venezuela Regime Change -- Barrons.com

3. jaan 2026, 17:40 UTC

Uudisväärsed sündmused

Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3. jaan 2026, 16:10 UTC

Uudisväärsed sündmused

What Maduro's Capture Means for Chevron Stock -- Barrons.com

3. jaan 2026, 15:53 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 15:03 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 14:10 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 12:16 UTC

Uudisväärsed sündmused

U.S. Captures Maduro, Trump Says -- Barrons.com

3. jaan 2026, 09:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

3. jaan 2026, 09:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

3. jaan 2026, 00:43 UTC

Omandamised, ülevõtmised, äriostud

Research Reports -- Barrons.com

2. jaan 2026, 22:13 UTC

Market Talk

Tulu

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Arbutus Biopharma Corp Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Arbutus Biopharma Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.255 / 3.365Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.